Context Initial treatment for most bladder cancers (BCs) involves transurethral resection
(TUR) or tumours. Often more cancer is found after the initial treatment in around half of …

Context Due to high recurrence rates, intensive surveillance strategies, and expensive
treatment costs, the management of bladder cancer contributes significantly to medical …

Abstract Context The European Association of Urology (EAU) panel on Non–muscle-
invasive Bladder Cancer (NMIBC) released an updated version of the guidelines on Non …

Abstract Context The first European Association of Urology (EAU) guidelines on bladder
cancer were published in 2002 [1]. Since then, the guidelines have been continuously …

Context Repeat transurethral resection (reTUR) is a guideline-recommended treatment
strategy in high-risk non–muscle-invasive bladder cancer (NMIBC) patients treated with …

More than 350,000 new cases of bladder cancer are diagnosed worldwide each year; the
vast majority (> 90%) of these are transitional cell carcinomas (TCC). The most important risk …

Background Clinical outcomes from non–muscle-invasive bladder cancer (NMIBC) are
partly determined by the quality of initial interventions. To improve and standardise treatment …

Diagnostic cystoscopy in combination with transurethral resection of the bladder tumour are
the standard for the diagnosis, surgical treatment and surveillance of bladder cancer. The …

Background White light (WL) is the established imaging modality for transurethral resection
of bladder tumour (TURBT). Narrow band imaging (NBI) is a promising addition. Objectives …

Purpose: Inflammation-based prognostic scores including neutrophil-to-lymphocyte ratio
(NLR), platelet-to-lymphocyte ratio (PLR), and lymphocyte-to-monocyte ratio (LMR) are …